Pacira Pharma (PCRX) Reports Publication of Phase 4 Study of EXPAREL in Cesarean Section Procedures in Anesthesia & Analgesia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. MRVL

Go back to Pacira Pharma (PCRX) Reports Publication of Phase 4 Study of EXPAREL in Cesarean Section Procedures in Anesthesia & Analgesia

Pacira Announces Publication of Phase 4 Study of EXPAREL in Cesarean Section Procedures in Anesthesia & Analgesia

August 5, 2020 7:31 AM EDT

Results show an opioid-reducing benefit of adding EXPAREL to bupivacaine transversus abdominis plane (TAP) blocks for cesarean delivery

PARSIPPANY, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that full results its Phase 4 study of EXPAREL® (bupivacaine liposome injectable suspension) administered via transversus abdominis plane (TAP) field block in patients undergoing Cesarean section (C-section) have been published in... More